We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is The FDA Keeping Us Fat?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Is The FDA Keeping Us Fat?
Business

Is The FDA Keeping Us Fat?

JohnCGoodman
JohnCGoodman
Share
3 Min Read
SHARE

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion.

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion. And the savings could be up to $35 billion if those individuals lost 10% of their body weight.

Despite this, last year the FDA rejected three new obesity therapies — Qnexa, Contrave, and Lorqess — the most promising of which, Qnexa, has been shown to bring about sustained weight loss greater than 10% of a person’s body weight. The FDA wanted additional evidence of the drugs were safe and effective in the short term; and evidence showing long-term weight loss. The rub is that the ingredients in two of the three therapies are known to be safe — they’re already FDA approved and widely available for treating migraines, depression, and other conditions. The first of the three drug makers is now going back to try again, having resubmitted its application for FDA approval.

Arguably, the main reason the FDA is hesitant to approve an obesity drug is because it considers nothing as safe for controlling weight as diet and exercise. However, diet and exercise generally fail. And there are few medications available — most of which are ineffective. That leaves surgery, a drastic step for many with a relatively high risk of death.

More Read

Irresistible Forces: HealthCare Costs
Holding Down Costs for Clinical Trial Recruitment
Consolidating 80 Websites: Chris Boyer [PODCAST]
Fundings in Medtech 2009-2014: A Contrarian View
To Increase Physician Productivity, Focus on Tools for Support Staff First

Without prescription weight-loss drugs, people turn to over-the-counter remedies, many of which are not very safe either. These include highly-caffeinated energy drinks that can raise blood pressure and herbal remedies bought on the Internet, many of which come from China and actually contain active ingredients that have been banned by the FDA.

   

TAGGED:FDAobesitypharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Administrator's Guide to Auditing Regulated Waste Before an OSHA Inspection -- AI-generated illustration
The Administrator’s Guide to Auditing Regulated Waste Before an OSHA Inspection
Policy & Law
August 31, 2026
What Geographic and Specialty Variation Reveals About How Nursing Compensation Actually Works -- AI-generated illustration
What Geographic and Specialty Variation Reveals About How Nursing Compensation Actually Works
Career Nursing
August 27, 2026
Could Poor Ventilation Be Behind Your Afternoon Headaches?  -- AI-generated illustration
Could Poor Ventilation Be Behind Your Afternoon Headaches? 
Health
August 27, 2026
The Myth That Keeps People Stuck -- AI-generated illustration
The Myth That Keeps People Stuck
Addiction Recovery
August 25, 2026

You Might also Like

Clinical Trial Marketing, Patient Recruitment, Patient Engagment
BusinesseHealthSocial Media

3 Ways to Keep Patients Engaged During Long-Term Clinical Trials

August 4, 2014

VIVUS, Inc., Presses the Case for Obesity Drug Qnexa, Market Success

October 18, 2011
Tax
Health ReformHospital AdministrationPolicy & LawTechnology

The Medical Device Sales Tax Suspension Could Be a Huge Opportunity – Don’t Let it Go to Waste

March 17, 2016
BusinessHospital AdministrationMedical InnovationsTechnology

Just Like Any New, Burgeoning Shiny New Object, Healthcare CRM Has Its Own Challenges

September 14, 2018
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?